OBJECTIVE
To evaluate the effectiveness of complex rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology during a one-year follow-up.
MATERIAL AND METHODS
A promising dynamic examination and treatment of 323 children with neuropsychiatric pathology from the age of 7 days to 1 year, age 3.2±1.7 months, divided into 2 groups: the 1st group included 117 children with acute hypoxic neuropsychiatric pathology; the 2nd consisted of 98 children with chronic hypoxic neuropsychiatric pathology. Patients of both groups were randomized into 2 subgroups: patients of subgroups 1A and 2A received 2 courses of Cortexin administration with an interval of 3 months. All patients received treatment in accordance with clinical guidelines. Clinical examination and electroencephalographic mapping were used to assess the effectiveness of therapy.
RESULTS
All the examined patients showed signs of myotonic syndrome, a short-term delay in the reduction of unconditional motor automatism, delayed formation of age-related physiological motor reflexes (installation chain reactions, visual-motor interactions, manual activity, balance and walking functions). According to neurosonography, parenchymal and ventricular hematomas and signs of hydrocephalus were detected in patients. In children of subgroups 1A and 2A, the frequency and severity of symptoms after therapy differed statistically significantly from those in patients of groups 1B and 2B. Against the background of Cortexin use, 73.4% of the examined subgroups 1A and 71.3% — 1B showed an increase in bioelectric activity in the range of 10—12 Hz, an increase in signal amplitude.
CONCLUSIONS
Acute hypoxic-ischemic damage to the central nervous system determines the predominance of myotonic syndrome, and chronic hypertension-hydrocephalus syndrome. Conducting two treatment courses with the inclusion of the drug Cortexin leads to a significant reduction in the frequency and severity of manifestations of myotonic and hypertensive-hydrocephalic syndromes in children with both acute and chronic hypoxic-ischemic central nervous system damage.
